A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about Longeveron Inc’s (LGVN) stock grades for Momentum, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Charles Griswold
| Share Statistics | LGVN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $23.0 | $277.2 | 11% |
|
| Shares Out (Mil) | 24.8 | 49.2 | 35% |
|
| Institutional Ownership | 42.8% | 92.1% | 18% |
|
| Float (Mil) | 26.3 | 40.0 | 34% |
|
| Beta | -0.38 | 0.94 | 2% |
|
| Avg Daily Volume (000s) | 313 | 485 | 51% |
|
| Price Change (52-week) |
(57.5%) | 55.5% | 12% |
|
| Growth | LGVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (26.5%) | 13.2% | 1% |
|
| Net Income (5yr) | (43.7%) | (10.0%) | 8% |
|
| EPS (5yr) | 11.1% | 16.0% | 48 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (4.7%) | (15.6%) | 61% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LGVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $37 | 2% |
|
| Net Income (TTM) (Mil) | ($22) | ($43) | 23% |
|
| EPS (TTM) | ($1.119) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | ($31) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $3 | 48% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $3 | 13% |
|
| Enterprise Value (Q1) (Mil) | $9 | $162 | 8% |
|
| Valuation | LGVN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.40 | 2.58 | 36% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | LGVN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 65.1% | 64.8% | 77% |
|
| Net Margin | na | (70.6%) | na |
|
| ROA | (106.7%) | (53.3%) | 5% |
|
| ROE | (135.2%) | (60.8%) | 7% |
|
| Liabilities to Assets | 24.4% | 31.5% | 17% |
|
| F-Score | 3 | 3 | 19% |
|
Longeveron Inc. did not pass any screens on 8/5/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
